Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Precancerous Conditions 1

Interventions

Cisplatin 53Paclitaxel 27Carboplatin 22Brachytherapy 18Radiotherapy 17human papillomavirus vaccine, L1 type 16, 18 12Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 12Gemcitabine 12Topotecan 8Vaccines, Synthetic 7Platinum 7Papillomavirus Vaccines 7Radiation 6Bevacizumab 61,2-diaminocyclohexaneplatinum II citrate 6Neoadjuvant Therapy 5Chemotherapy, Adjuvant 5pembrolizumab 4Vinorelbine 4Radiotherapy, Intensity-Modulated 4Pemetrexed 4Drug Therapy 4Taxes 3Surgical Procedures, Operative 3Ondansetron 3Irinotecan 3Dexamethasone 3Chemoradiotherapy 3tisotumab vedotin 2specific substance maruyama 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Uterine Cervical Neoplasms × Polymerase Chain Reaction × Clear all
NCT00462813 2013-08-07

Diindolylmethane in Treating Patients With Abnormal Cervical Cells

National Cancer Institute (NCI)

Phase 3 Completed
3,000 enrolled
GynecologicOther neoplasm

Uterine Cervical Dysplasia, Uterine Cervical Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡